Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Juan Schmukler

Rheumatology Chicago, IL Medical Doctor

NPI 1538423975 CMS profile 805654

1901 W Harrison St, Chicago, IL 60612

Open in the dashboard

General payments

$1,538

82 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Juan Schmukler of Chicago, IL is reported in the CMS Open Payments database as having received $1,538 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $194 9
2021 General $496 27
2020 General $316 19
2019 General $533 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juan Schmukler
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Juan Schmukler were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Juan Schmukler Rheumatology median Middle half National median
2019 $533 $744 $153–$2,687 $163
2020 $316 $462 $98–$2,027 $114
2021 $496 $531 $101–$2,153 $132
2022 $194 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AbbVie, Inc. $689 39 payments
  2. Amgen Inc. $507 25 payments
  3. E.R. Squibb & Sons, L.L.C. $205 12 payments
  4. Horizon Therapeutics plc $38 2 payments
  5. Janssen Scientific Affairs, LLC $28 1 payment
  6. Janssen Pharmaceuticals, Inc $28 1 payment
  7. Mallinckrodt Enterprises LLC $25 1 payment
  8. GlaxoSmithKline, LLC. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $1,535 81 payments
  2. Education $4 1 payment
Products named General payments · program years 2019–2022
  1. HUMIRA $417 24 payments
  2. Prolia $227 13 payments
  3. EVENITY $170 10 payments
  4. ORENCIA $167 9 payments
  5. Enbrel Inflammation $160 7 payments
  6. RINVOQ Immunology $156 9 payments
  7. RINVOQ Immunology $101 7 payments
  8. Enbrel Inflammation $77 3 payments
  9. AIMOVIG $61 3 payments
  10. Repatha $61 3 payments
  11. Other $239 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

930

Median for Rheumatology: 1,511

Drug cost

$2,097,710

Median for Rheumatology: $1,139,948

Branded share of claims

38%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 91 $683,421
Krystexxa Pegloticase Brand 21 $565,168
Rinvoq Upadacitinib Brand 33 $202,301
Enbrel Sureclick Etanercept Brand 26 $187,016
Enbrel Etanercept Brand 14 $98,953
Actemra Actpen Tocilizumab Brand 21 $90,407
Xeljanz Xr Tofacitinib Citrate Brand 14 $73,849
Forteo Teriparatide Brand 16 $69,039
Orencia Clickject Abatacept Brand 13 $66,953
Kevzara Sarilumab Brand 11 $47,488

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$29,921

Medicare's payments for the services billed

Medicare patients

179

Average age 72

Services billed

516

130 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Osteoporosis 39%
Ischemic heart disease 33%
Chronic kidney disease 30%
Heart failure 25%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record